This is a summary of the European public assessment report (EPAR) for PritorPlus. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for PritorPlus.
Therapeutic Indication
### Therapeutic indication Treatment of essential hypertension. PritorPlus fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide, 80mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone. PritorPlus fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on PritorPlus (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.
Therapeutic Area (MeSH)
ATC Code
C09DA07
ATC Item
telmisartan and diuretics
Pharmacotherapeutic Group
Agents acting on the renin-angiotensin system
Active Substance (Summary)
INN / Common Names
EMA Name
PritorPlus
Medicine Name
PritorPlus
Aliases
N/ANo risk management plan link.
